First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study

Rheumatology and Therapy

Volumn 3, Issue 2, 2016, Pages 271-290

  Schwarting, Andreas ^a   Schroeder, Johann O ^b   Alexander, Tobias ^c   Schmalzing, Marc ^d   Fiehn, Christoph ^e   Specker, Christof ^f   Perna, Alessandra ^g   Cholmakow Bodechtel, Constanze ^h   Koscielny, Volker B ^g   Carnarius, Heike ⁱ  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e ACURA Centre for Rheumatic Diseases   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g GLAXOSMITHKLINE   (United Kingdom)

^h KANTAR HEALTH   (United States)

ⁱ GLAXOSMITHKLINE   (Germany)

Author keywords

B cell targeted therapy; Belimumab; Observational study; SLE; Systemic lupus erythematosus

Indexed keywords

EID: 85016172853     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-016-0047-x     Document Type: Article

References (37)

1. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934–40. DOI: 10.1002/art.20666
2. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28. DOI: 10.1056/NEJMoa043731
3. Lutalo PMK, Jordan N, D’Cruz DP. Which dose of steroids and which cytotoxics for severe lupus? Presse Med. 2014;(6 Pt 2):e157–65. DOI: 10.1016/j.lpm.2014.03.001
4. Nørgaard JC, Stengaard-Pedersen K, Nørgaard M, de Thurah A. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. Lupus. 2015;24(3):299–306.
5. Petri M, Bechtel B, Dennis G, et al. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. Lupus. 2014;23(10):1006–13. DOI: 10.1177/0961203314532699
6. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatol (Oxford). 2014;53(8):1470–6. DOI: 10.1093/rheumatology/keu148
7. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–67. DOI: 10.1136/annrheumdis-2013-205139
8. Brugos B, Sebestyen L, Tarr T, Vincze Z. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Pharm. 2014;69(6):442–4.
9. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015;11(1):46–61. DOI: 10.1038/nrneph.2014.215
10. Leone A, Sciascia S, Kamal A, Khamashta M. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol. 2015;11(1):109–16. DOI: 10.1586/1744666X.2015.994508
11. Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13(11):1094–101. DOI: 10.1016/j.autrev.2014.08.020
12. Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA. New treatments for inflammatory rheumatic disease. Immunol Res. 2014;60(2–3):277–88. DOI: 10.1007/s12026-014-8565-5
13. EMA. Benlysta-European public assessment report (EPAR) Product Information—EMEA/H/C/002015-IB/0030/G. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002015/WC500110150.pdf. Accessed 15 Dec 2016.
14. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. DOI: 10.1002/art.30613
15. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2
16. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9. DOI: 10.1136/annrheumdis-2011-200937
17. Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus. 2013;22(4):372–80. DOI: 10.1177/0961203313476154
18. Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin North Am. 2014;40(3):507–17. DOI: 10.1016/j.rdc.2014.04.007
19. Lutalo PMK, D’Cruz DP. Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther. 2014;14(11):1701–8. DOI: 10.1517/14712598.2014.959924
20. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65. DOI: 10.1002/art.11299
21. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Investig. 2009;119(5):1066–73. DOI: 10.1172/JCI38010
22. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37. DOI: 10.1002/art.34400
23. Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118. doi:10.1136/lupus-2015-000118. DOI: 10.1136/lupus-2015-000118
24. Cortes J, Andreu JL, Calvo-Alen J, et al. Evolution of patients with systemic lupus erythematous treated with belimumab in clinical practice settings. Arthritis Rheumatol. 2014;66(Suppl 11):S291.
25. Mosca M, van Vollenhoven R. New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S82–5.
26. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205. DOI: 10.1136/ard.2007.070367
27. Cervera R, Doria A, Amoura Z, et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev. 2014;13(6):621–9. DOI: 10.1016/j.autrev.2013.11.007
28. Rao V, Gordon C. Advances in the assessment of lupus disease activity and damage. Curr Opin Rheumatol. 2014;26(5):510–9. DOI: 10.1097/BOR.0000000000000085
29. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51. DOI: 10.1002/art.24698
30. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatol (Oxford). 2012;51(7):1145–53. DOI: 10.1093/rheumatology/ker410
31. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–20. DOI: 10.1016/j.amjmed.2008.09.030
32. Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–54. DOI: 10.1177/0961203312469259
33. Askanase AD. Clinical response to belimumab in academic clincal practices. Ann Rheum Dis. 2014;73(Suppl 2):521–2. DOI: 10.1136/annrheumdis-2014-eular.6149
34. Brito Zeron P, Caminal-Montero L, Chamorro A, et al. Blocking the human B lymphocyte stimulator molecule (BLyS) using a monoclonal antibody (belimumab) in Systemic lupus erythematosus: first results in real-life spanish patients with refractory disease (biogeas-Semi Registry). Ann Rheum Dis. 2014;73(Suppl 2):985.
35. Ke X, Patel J, Kan H, Eisenberg DF, Oglesby A. Characteristics and medication use patterns among belimumab users in a commercially insured population with systemic lupus erythematosus. Arthritis Rheum. 2013;65(Suppl 10):1070.
36. Iaccarino L, Bettio S, Ghirardello A, et al. Preliminary data on the efficacy of belimumab in the “real-Life”: a single centre experience. Proceedings of the 9th international congress on autoimmunity; 2014 26–30 March; Nice, France.
37. Majdan M, Kucharz EJ, Jeka S, Sierakowski S, Leszczynski P, Tlustochowicz W, et al. Early clinical experiences with belimumab in Polish patients with systemic lupus erythematosus. Ann Rheum Dis. 2014;73(Suppl 2):970. DOI: 10.1136/annrheumdis-2014-eular.2880